Efficacy of First-Line Immunotherapy in Metastatic Melanoma in Slovenia and Identification of Predictive Biomarkers

Recruiting now · Not applicable

Conditions studied: Metastatic Melanoma, Melanoma

In brief

This study evaluates the effectiveness of first-line immunotherapy in patients with metastatic melanoma treated at the Institute of Oncology Ljubljana in Slovenia. The main objectives are to assess treatment response rates, progression-free survival, and treatment safety, and to identify prognostic and predictive biomarkers associated with response to immunotherapy. Biological samples including blood, stool, and body fluids (if available) will be collected at predefined time points and analyzed for molecular tumor markers. Imaging assessments (CT or PET/CT) will be performed before treatment initiation and during follow-up to evaluate response. The study aims to improve identification of patient subgroups who benefit from immunotherapy and those who do not, supporting better personalized treatment strategies.

Key facts

Study ID

NCT07407166

Run by

Institute of Oncology Ljubljana

People needed

40

Starts

2021-05-01

Expected to finish

2027-12-31

Last updated by the study team

2026-02-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥ 18 years
• Metastatic (diffuse) melanoma
• Planned first-line immunotherapy treatment
• Signed informed consent for participation in the study

You may not qualify if…

• Age < 18 years
• Inability to provide informed consent
• Any condition preventing participation or sample collection according to investigator judgment

Where it is running

• Institute of Oncology Ljubljana — Ljubljana, Slovenia (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.